When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?

Jared R. Adams*, Cara Angelotta, Charles L. Bennett

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

18 Scopus citations

Fingerprint

Dive into the research topics of 'When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?'. Together they form a unique fingerprint.